Antidepressant-like effects of the aqueous macerate of the bulb of Gladiolus dalenii Van Geel (Iridaceae) in a rat model of epilepsy-associated depression

BMC Complementary and Alternative Medicine

Willie Mark Uren Daniels¹  Elisabeth Ngo Bum³  Gwladys Temkou Ngoupaye² 

[1]Discipline of Human Physiology, School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa

[2]Laboratory of Physiology and Phytopharmacology, Department of Animal Biology, University of Dschang, P.O. BOX: 67, Dschang, Cameroon

[3]Department of Biological Science, University of Ngaoundéré, Ngaoundéré, Cameroon

关键词: Gladiolus dalenii;    BDNF;    HPA axis;    Epilepsy;    Depression;   

Others  :  1220888
DOI  :  10.1186/1472-6882-13-272

 received in 2013-04-17, accepted in 2013-10-09,  发布年份 2013

【 摘 要 】

Background

In Cameroonian traditional medicine various extracts of Gladiolus dalenii Van Geel (Iridaceae) have been used as a cure for various ailments that include headaches, digestive problems, muscle and joint aches, and some central nervous system disorders such as epilepsy, schizophrenia and mood disorders. Owning to this background, the aim of the study was to investigate whether an aqueous macerate of the bulb of Gladiolus dalenii has any antidepressant activity focusing specifically on depression-like behaviours associated with epilepsy.

Method

We used the combined administration of atropine and pilocarpine to rats as our animal model of epilepsy. The forced swim test and spontaneous locomotor activity in the open field test were the two tools used to assess the presence of depression-like behaviour in epileptic and control animals. The following depression-related parameters were determined: plasma ACTH, plasma corticosterone, adrenal gland weight and hippocampal levels of brain-derived neurotrophic factor (BDNF). The effects of Gladiolus dalenii were compared to that of fluoxetine.

Results

Our results showed that we had a valid animal model of epilepsy-induced depression as all 3 measures of construct, predictive and face validity were satisfied. The data indicated that Gladiolus dalenii significantly reduced the immobility times in the forced swim test and the locomotor activity as assessed in the open field. A similar pattern was observed when the HPA axis parameters were analysed. Gladiolus dalenii significantly reduced the levels of ACTH, corticosterone, but not the adrenal gland weight. Gladiolus dalenii significantly increased the level of BDNF in the hippocampus. In all parameters measured the effects of Gladiolus dalenii were significantly greater than those of fluoxetine.

Conclusion

The results show that Gladiolus dalenii has antidepressant-like properties similar to those of fluoxetine in epilepsy-associated depressive states. The antidepressant activity of Gladiolus dalenii is likely to be mediated by restoring the activity of the HPA axis and increasing the levels of BDNF in the hippocampus.

【 授权许可】

   
2013 Ngoupaye et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Kessler RC: Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys. J Am Med Assoc 2004, 291:2581-2590.
• [2]Eisenberg JM: Medicines for treating depression: a review of the research for adults. AHRQ Comp Eff Rev 2012. http://www.ahrq.gov webcite
• [3]Frazer A: Pharmacology of antidepressants. J Clin Psychopharmacol 1997, 17(1):2-18.
• [4]Pineda E, Shin D, Sankar R, Mazarati MA: Comorbidity between epilepsy and depression: experimental evidence for the involvement of serotonergic, glucocorticoid, and neuroinflammatory mechanisms. Epilepsia 2010, 51:110-114.
• [5]Mahomoodally MF: Recent advances to evaluate anti-diabetic medicinal plants. In Medicinal Plants: Biodiversity and Drugs. Edited by Rai MK, Cordell G, Jose LM. New York, USA: Science Publishers CRC Press: Taylor and Francis; 2012:526-569.
• [6]Sahib NG, Saari N, Ismail A, Khatib A, Mahomoodally F, Hamid AA: Plants’metabolites as potential antiobesity agents. Sci World J 2012. doi:10.1100/2012/436039
• [7]Etet PFS, Mahomoodally MF: New insights in staging and chemotherapy of African trypanosomiasis and possible contribution of medicinal plants. Sci World J 2012. doi:10.1100/2012/343652
• [8]Goldblatt P: Gladiolus of Tropical Africa. Oregon: Timber Press Portland; 1996:321.
• [9]Burkill HM: The Flora of West Tropical Africa. 2nd edition. London: Kew: Royal Botanic Gardens; 1985.
• [10]Bandeira SO, Gaspar F, Pagula FP: Ethnobotany and healthcare in Mozambique. Pharm Biol 2001, 39:70-73.
• [11]Ngoupaye GT, Ngo Bum E, Ngah E, Talla E, Moto FCO, Taiwe GS, Rakotonirina A, Rakotonirina SV: The anticonvulsant and sedative effects of Gladiolus dalenii extracts in mice. Epilepsy Behav 2013, 28:450-456.
• [12]Carlat D: Evidence-based somatic treatment of depression in adults. Psychiatr Clin North America 2012, 35:131-142.
• [13]Covolan L, Smith RL, Mello LE: Ultrastructural identification of dentate granule cell death from pilocarpine-induced seizures. Epilepsy Res 2000, 41:9-21.
• [14]Mello LE, Cavalheiro EA, Tan AM: Circuit mechanisms of seizures in the pilocarpine model of chronic epilepsy: cell loss and mossy fiber sprouting. Epilepsia 1993, 34:985-995.
• [15]Paulose CS, Chathu F, Khan RS, Krishnakumar A: Neuroprotective role of Bacopamonnieri extract in epilepsy and effect of glucose supplementation during hypoxia: glutamate receptor gene expression. Neurochem Res 2008, 33:1663-1671.
• [16]Turski WA, Cavalheiro EA, Schwarz M, Czuczwar SLJ, Kleinrok Z, Turski L: Limbic seizures produced by pilocarpine I rats: behavioral, electroencephalographic and neuropathological study. Behav Brain Res 1983, 9:315-335.
• [17]Turski WA, Czuczwar SJ, Kleinrok Z, Turski L: Cholinomimetics produce seizures and brain damage in rats. Experientia 1983b, 39:1408-1411.
• [18]Curia G, Longo D, Biagini G, Jonesc SGR, Avoli M: The pilocarpine model of temporal lobe epilepsy. J Neurosci Methods 2008, 172:143-157.
• [19]Price JL, Drevets WC: Neurocircuitry of mood disorders. Neuropsychopharmacol 2010, 35:192-216.
• [20]Autry AE, Monteggia LM: Brain-derived neurotrophic factor and neuropsychiatric disorders. Pharmacol Rev 2012, 64:238-258.
• [21]Racine RJ: Modification of seizure activity by electrical stimulation: after discharge threshold. Electroencephalogr Clin Neurophysiol 1972, 32:269-279.
• [22]Porsolt RD, Le Pichon M, Jalfre M: Depression: a new animal model sensitive to antidepressant treatments. Nature 1977, 266:730-732.
• [23]Cannizzaro C, Martire M, Cannizzaro E, Provenzano G, Gagliano M, Carollo A, Mineo A, Steardo L: Long lasting handling affects behavioural reactivity in adult rats of both sexes prenatally exposed to diazepam. Brain Res 2001, 904:225-233.
• [24]Kanner AM: Epilepsy, suicidal behaviour, and depression: do they share common pathogenic mechanisms? Lancet Neurol 2006, 5:107-108.
• [25]Kanner AM: Depression and epilepsy: a new perspective on two closely related disorders. Epilepsy Curr 2006, 6:141-146.
• [26]Garcia CS: Depression in temporal lobe epilepsy: a review of prevalence, clinical features, and management considerations. Epilepsy Res Treat 2012. doi: 10.1155/2012/809843
• [27]Covolan L, Mello LE: Temporal profile of neuronal injury following pilocarpine or kainic acid-induced status epilepticus. Epilepsy Res 2000, 39:133-152.
• [28]Kondziella D, Alvestad S, Vaaler A, Sonnewald U: Which clinical and experimental data link temporal lobe epilepsy with depression? J Neurochem 2007, 103:2136-2152.
• [29]Steru L, Chermat R, Thierry J, Simon P: The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacol 1985, 85:367-370.
• [30]Porsolt RD, Bertin A, Blavet M, Jalfre M: Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur J Pharmacol 1978, 47:379-391.
• [31]Dar A, Khatoon S: Behavioural and biochemical studies of dichloromethane fraction from the Areca catechu nut. Pharmacol Biochem Behav 2000, 65:1-6.
• [32]Sousa FCF, Melo CTV, Monteiro AP, Lima VTM, Gutierrez SJC, Pereira BA, Barbosa-Filho JM, Vasconcelos SMM, Fonteles MF, Viana GSB: Antianxiety and antidepressant effects of Riparin III from Aniba riparia (Nees) Mez (Lauraceae) in mice. Pharmacol Biochem Behav 2004, 78:27-33.
• [33]Novas M, Wolfman C, Medina JH, De Robertis E: Proconvulsant and anxiogenic effects of n-butyl-β-carboline-3-carboxylate, on endogenous benzodiazepine binding inhibitor from brain. Pharmacol Biochem Behav 1988, 30:331-336.
• [34]Ji CX, Li XY, Jia SB, Liu LL, Ge YC, Yang QX, Zhang JJ: The antidepressant effect of Cynanchumauriculatum in mice. Pharm Biol 2012, 50:1067-1072.
• [35]Slattery DA, Cryan JF: Using the rat forced swim test to assess antidepressant-like activity in rodents. Nat Protoc 2012, 7:1009-1014.
• [36]Mason BL, Pariante CM: The effects of antidepressants on the hypothalamic-pituitary-adrenal axis. Drug News Perspect 2006, 19:603-608.
• [37]Groves JO: Is it time to reassess the BDNF hypothesis of depression? Mol Psychiatry 2007, 12:1079-1088.
• [38]Martinowich K, Manji H, Lu B: New insights into BDNF function in depression and anxiety. Nat Neurosci 2007, 10:1089-1093.
• [39]Nibuya M, Morinobu S, Duman RS: Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosc 1995, 15:7539-7547.
• [40]Duman RS, Monteggia LM: A neurotrophic model for stress-related mood disorders. Biol Psychiatry 2006, 59:1116-1127.
• [41]Angelucci F, Brene S, Mathe AA: BDNF in schizophrenia, depression and corresponding animal models. Mol Psychiatry 2005, 10:345-352.
• [42]Mazarati AM, Siddarth P, Baldwin RA, Shin D, Caplan R, Sankar R: Depression after status epilepticus: behavioural and biochemical deficits and effects of fluoxetine. Brain 2008, 131:2071-2083.